BMY · Bristol-Myers Squibb Co
United States · RS rating 64 · As of 2026-10-14
| Price | 59.28 USD |
|---|---|
| 1-day change | +4.6% |
| RS rating (overall / 1M / 3M / 12M) | 64 / 33 / 59 / 87 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 39 / 46 / 33 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | -50.9% |
| Sales growth Q/Q | +2.3% |
| Distance from 52-week high | +12.9% |
| Market cap (USD) | $120.5B |